865626-62-6

Upstream product

• 707-07-3 orthobenzoic acid trimethyl ester 
• 288154-18-7 tert-butyl 4-amino-4-carbamoylpiperidine-1-carboxylate 
• 635713-70-1 4-benzoylamino-4-cyano-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 635713-69-8 2-phenyl-1,3,8-triaza-spiro[4.5]dec-1-en-4-one 
• 943145-62-8 2-phenyl-1,3,8-triaza-spiro[4.5]dec-1-en-4-one, hydrochloride 

Relevant academic research and scientific papers

CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of Formula I: Formula I: I and Formula II: (where variables R1, R2, R3, R4, A, B, J, Q, T, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Novel therapeutic agents for the treatment of migraine

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their u

Calcitonin gene related peptide receptor antagonists

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.